Automate Your Wheel Strategy on ABBV
With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABBV
- Rev/Share 34.352
- Book/Share -1.8131
- PB -124.9432
- Debt/Equity -21.0624
- CurrentRatio 0.6713
- ROIC 0.1057
- MktCap 405578362400.0
- FreeCF/Share 10.5039
- PFCF 21.6875
- PE 96.6787
- Debt/Assets 0.5141
- DivYield 0.029
- ROE -3.6158
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABBV | Barclays | -- | Overweight | -- | $275 | Feb. 20, 2026 |
| Downgrade | ABBV | Wolfe Research | Outperform | Peer Perform | -- | -- | Jan. 8, 2026 |
| Resumed | ABBV | UBS | -- | Neutral | -- | $240 | Jan. 7, 2026 |
| Upgrade | ABBV | HSBC Securities | Hold | Buy | -- | $265 | Dec. 10, 2025 |
| Initiation | ABBV | Scotiabank | -- | Sector Outperform | -- | $280 | Nov. 13, 2025 |
| Downgrade | ABBV | DZ Bank | Buy | Hold | -- | $237 | Nov. 4, 2025 |
| Downgrade | ABBV | Erste Group | Buy | Hold | -- | -- | Oct. 14, 2025 |
| Downgrade | ABBV | HSBC Securities | Buy | Hold | -- | -- | Oct. 1, 2025 |
| Upgrade | ABBV | Berenberg | Hold | Buy | -- | $270 | Sept. 17, 2025 |
| Resumed | ABBV | Piper Sandler | -- | Overweight | -- | $231 | Aug. 12, 2025 |
News
Here's Why AbbVie (ABBV) is a Strong Growth Stock
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
Published: February 23, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Read More
Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie ABBV announced encouraging fourth-quarter and full-year 2025 results earlier this month that beat expectations. A major portion of the company's top-line growth came from its newer immunology medicines, Rinvoq and Skyrizi, which not only mitigated the impact of continued erosion in legacy drug Humira but also reaffirmed their role as AbbVie's key growth drivers.
Read More
AbbVie Declares Quarterly Dividend
Published: February 19, 2026 by: PRNewsWire
Sentiment: Neutral
NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
Read More
AbbVie Down Since Q4 Earnings Report: How to Play the Stock
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Negative
ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.
Read More
Why AbbVie (ABBV) is a Top Momentum Stock for the Long-Term
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Published: February 13, 2026 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (ABBV) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Read More
Here's Why AbbVie (ABBV) is a Strong Value Stock
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Read More
Dividend Kings: No Ideal Buys In February's 57
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Neutral
Dividend Kings remain broadly overvalued, with only a handful approaching fair price despite elevated yields. Three Dividend Kings—Canadian Utilities, Fortis, and Hormel—currently meet the dogcatcher 'ideal' but face dividend safety concerns due to negative free cash flow margins. Analyst projections estimate 14.16% to 27.77% net gains for top-yielding Dividend Kings by February 2027, with ABBV and NWN ranking in the top 20 across yield, target, and returns.
Read More
Here's What Will Drive AbbVie's Top-line Growth in 2026
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
Read More
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal
Published: February 05, 2026 by: MarketBeat
Sentiment: Positive
When the price of a high-quality stock such as AbbVie NYSE: ABBV declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to buy.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Negative
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 adjusted EPS guidance of $14.37–$14.57 excludes unpredictable IPR&D and milestone costs, raising concerns about reliance on M&A for future growth.
Read More
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
Read More
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
Read More
AbbVie (ABBV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
AbbVie (ABBV) Tops Q4 Earnings and Revenue Estimates
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) came out with quarterly earnings of $2.71 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.16 per share a year ago.
Read More
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
Published: February 03, 2026 by: PRNewsWire
Sentiment: Neutral
The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences. Natrelle® champions women's voices to provide support at every step of their breast aesthetics journey.
Read More
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.
Read More
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
10 Highest Rated Dividend Kings For Generations Of Income
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Positive
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend safety/growth grades, and favorable Quant, SA, and Wall Street ratings. ABM Industries leads with a low 31% payout ratio, 2.5% yield, B- safety/growth, and an A- valuation grade despite a Hold Quant rating.
Read More
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is the Options Market Predicting a Spike in AbbVie Stock?
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors need to pay close attention to ABBV stock based on the movements in the options market lately.
Read More
The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
Published: January 27, 2026 by: Business Wire
Sentiment: Neutral
CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premier health care incubator and innovation hub, announced today a call for applications for the 2026 AbbVie Foundation Health Equity Accelerator. Now in its second year, the accelerator provides resources and coaching to select nonprofit organizations to advance their innovative solutions that expand a.
Read More
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
Read More
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
Based on the topline results from the EPCORE® DLBCL-1 trial, AbbVie along with partner Genmab will engage global regulatory authorities to discuss next steps NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Read More
AbbVie plans to build out its presence in obesity market
Published: January 14, 2026 by: Reuters
Sentiment: Positive
AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra.
Read More
About AbbVie Inc. (ABBV)
- IPO Date 2013-01-02
- Website https://www.abbvie.com
- Industry Drug Manufacturers - General
- CEO Scott T. Reents
- Employees 55000